CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.
Read in depth: Business
Etsy restricts AI-generated patterns and recipes under new seller rules
Sellers must show real results for instructional downloads and disclose AI use in permitted artwork as Etsy tightens its marketplace rules.
Telegraph begins redundancy consultation as Axel Springer sets out AI-led expansion
Telegraph Media Group has begun consulting staff over job cuts while outlining plans to reorganise the publisher, expand abroad and develop new revenue streams. It has not...
Sources and context
ReutersSource headline and summary supplied via NewsData.io. First collected by NewsJaws on 2026-10-05. This is an automated news brief, not original NewsJaws reporting. Dates reflect the source publication. Feed delays may apply.